Role of sequencing in therapy selection

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The goals of sequencing antiretroviral agents are to preserve as many treatment options as possible, minimize drug toxicity, and prolong suppression of HIV. There are numerous options for sequencing antiretroviral agents when treatment fails. The most common reasons for treatment failure are the emergence of resistance and poor adherence. Data indicate that protease inhibitor therapy enhanced by ritonavir may delay the development of resistance longer than nonboosted protease inhibitor therapy. The results of using efavirenz or abacavir to simplify protease inhibitor treatment regimens for HIV-suppressed patients are promising. Although resistance to nonnucleoside reverse transcriptase inhibitors is a serious problem, sequencing them after zidovudine or abacavir therapy may be effective because of the hypersusceptibility to nonnucleoside reverse transcriptase inhibitors exhibited by viral populations in many nucleoside reverse transcriptase inhibitor-experienced patients. New antiretrovirals with greater tolerability, higher genetic barriers, and less cross-resistance than existing agents are needed to achieve further dramatic advances in treating HIV infection.

Original languageEnglish (US)
JournalJournal of Acquired Immune Deficiency Syndromes
Volume29
Issue numberSUPPL. 1
StatePublished - Feb 1 2002
Externally publishedYes

Fingerprint

Reverse Transcriptase Inhibitors
Protease Inhibitors
Anti-Retroviral Agents
efavirenz
Therapeutics
HIV
Ritonavir
Zidovudine
Drug-Related Side Effects and Adverse Reactions
Treatment Failure
Nucleosides
HIV Infections
Population
abacavir

Keywords

  • Antiretroviral sequencing
  • Highly active antiretroviral therapy (HAART) sequencing options
  • Sequencing decisions in antiretroviral therapy (ART)

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Role of sequencing in therapy selection. / Keiser, Philip.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 29, No. SUPPL. 1, 01.02.2002.

Research output: Contribution to journalArticle

@article{9bc6e5ad38b24a4b8cfa03f368f53ab5,
title = "Role of sequencing in therapy selection",
abstract = "The goals of sequencing antiretroviral agents are to preserve as many treatment options as possible, minimize drug toxicity, and prolong suppression of HIV. There are numerous options for sequencing antiretroviral agents when treatment fails. The most common reasons for treatment failure are the emergence of resistance and poor adherence. Data indicate that protease inhibitor therapy enhanced by ritonavir may delay the development of resistance longer than nonboosted protease inhibitor therapy. The results of using efavirenz or abacavir to simplify protease inhibitor treatment regimens for HIV-suppressed patients are promising. Although resistance to nonnucleoside reverse transcriptase inhibitors is a serious problem, sequencing them after zidovudine or abacavir therapy may be effective because of the hypersusceptibility to nonnucleoside reverse transcriptase inhibitors exhibited by viral populations in many nucleoside reverse transcriptase inhibitor-experienced patients. New antiretrovirals with greater tolerability, higher genetic barriers, and less cross-resistance than existing agents are needed to achieve further dramatic advances in treating HIV infection.",
keywords = "Antiretroviral sequencing, Highly active antiretroviral therapy (HAART) sequencing options, Sequencing decisions in antiretroviral therapy (ART)",
author = "Philip Keiser",
year = "2002",
month = "2",
day = "1",
language = "English (US)",
volume = "29",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Role of sequencing in therapy selection

AU - Keiser, Philip

PY - 2002/2/1

Y1 - 2002/2/1

N2 - The goals of sequencing antiretroviral agents are to preserve as many treatment options as possible, minimize drug toxicity, and prolong suppression of HIV. There are numerous options for sequencing antiretroviral agents when treatment fails. The most common reasons for treatment failure are the emergence of resistance and poor adherence. Data indicate that protease inhibitor therapy enhanced by ritonavir may delay the development of resistance longer than nonboosted protease inhibitor therapy. The results of using efavirenz or abacavir to simplify protease inhibitor treatment regimens for HIV-suppressed patients are promising. Although resistance to nonnucleoside reverse transcriptase inhibitors is a serious problem, sequencing them after zidovudine or abacavir therapy may be effective because of the hypersusceptibility to nonnucleoside reverse transcriptase inhibitors exhibited by viral populations in many nucleoside reverse transcriptase inhibitor-experienced patients. New antiretrovirals with greater tolerability, higher genetic barriers, and less cross-resistance than existing agents are needed to achieve further dramatic advances in treating HIV infection.

AB - The goals of sequencing antiretroviral agents are to preserve as many treatment options as possible, minimize drug toxicity, and prolong suppression of HIV. There are numerous options for sequencing antiretroviral agents when treatment fails. The most common reasons for treatment failure are the emergence of resistance and poor adherence. Data indicate that protease inhibitor therapy enhanced by ritonavir may delay the development of resistance longer than nonboosted protease inhibitor therapy. The results of using efavirenz or abacavir to simplify protease inhibitor treatment regimens for HIV-suppressed patients are promising. Although resistance to nonnucleoside reverse transcriptase inhibitors is a serious problem, sequencing them after zidovudine or abacavir therapy may be effective because of the hypersusceptibility to nonnucleoside reverse transcriptase inhibitors exhibited by viral populations in many nucleoside reverse transcriptase inhibitor-experienced patients. New antiretrovirals with greater tolerability, higher genetic barriers, and less cross-resistance than existing agents are needed to achieve further dramatic advances in treating HIV infection.

KW - Antiretroviral sequencing

KW - Highly active antiretroviral therapy (HAART) sequencing options

KW - Sequencing decisions in antiretroviral therapy (ART)

UR - http://www.scopus.com/inward/record.url?scp=0036471410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036471410&partnerID=8YFLogxK

M3 - Article

VL - 29

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - SUPPL. 1

ER -